# Inozyme Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inozyme-pharma

- Industry: Pharmaceuticals
- Headquarters: Boston, US
- Website: www.inozyme.com
- Total disclosed funding: $83M
- Latest round: Series A (Jun 8, 2020)
- Investors on record: 9

## About

Inozyme Pharma Inc, based in the US, focuses on developing innovative therapies for rare diseases linked to the PPi-Adenosine Pathway, aiming to improve patient health outcomes.Founded in 2016, Inozyme Pharma Inc is engaged in developing therapies for rare diseases. The company is headquartered in Boston, US. Led by Axel Bolte, who has a background in founding other biopharmaceutical companies, Inozyme has participated in a total of 9 deals, with its most recent funding occurring on July 27, 2023, when it raised USD 270.00 mn through an Add-on Trade Sale. The company has successfully raised a total of USD 64.50 mn, with BioMarin Pharmaceutical Inc. being one of its latest investors.Inozyme Pharma specializes in investigational therapies targeting rare diseases related to the PPi-Adenosine Pathway, crucial for healthy bone and blood vessel maintenance. Its product pipeline includes potential treatments for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, all lacking approved therapies. These investigational products aim to enhance the quality of life for patients affected by these conditions, with the company actively conducting clinical trials across North America and Europe to assess the efficacy of its therapies.Inozyme Pharma generates revenue primarily through clinical trial activities and the development of investigational therapies, supported by partnerships, grants, and anticipated future product sales. The company engages in B2B transactions with healthcare providers and research institutions, enrolling participants in clinical trials for its novel therapies. While specific pricing for investigational products is not disclosed, revenue prospects are linked to successful commercialization and strategic collaborations.Inozyme Pharma aims to leverage its recent funding of USD 60 mn from the private placement on July 27, 2023, to accelerate the development of its new therapies. The company is focused on expanding its clinical trials for existing products and exploring new markets in North America and Europe. This funding will support ongoing research and development initiatives, with the goal of bringing its novel therapies to market and addressing the unmet needs of patients with rare diseases.

## Funding rounds

- Series A, Jun 8, 2020, $34M — New Enterprise Associates, Sofinnova Investments, Novo Holdings, Longitude Capital, Sanofi Ventures, RA Capital Management, Rock Springs Capital, Cowen Investment Management, Pivotal Life Sciences
- Series A, Jan 17, 2017, $49M — New Enterprise Associates, Novo Holdings, Longitude Capital, Sanofi Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Novo Holdings — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Rock Springs Capital — Series A
- Cowen Investment Management — Series A
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series A